 Novavax NASDAQ: NVAX stock, a big Covid-19 vaccine play in 2020, fell 15 overnight on plans to raise 250 million in debt and equity. The plan is to offer 125 million in debt and 125 million in common stock, including options to underwriters for 18.75 million more at the public offering price, less underwriting discounts and commissions. 